BRPI0518191A - métodos e composições para reduzir a toxicidade de um composto farmacêutico - Google Patents

métodos e composições para reduzir a toxicidade de um composto farmacêutico

Info

Publication number
BRPI0518191A
BRPI0518191A BRPI0518191-7A BRPI0518191A BRPI0518191A BR PI0518191 A BRPI0518191 A BR PI0518191A BR PI0518191 A BRPI0518191 A BR PI0518191A BR PI0518191 A BRPI0518191 A BR PI0518191A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compound
compositions
methods
solutions
toxicity
Prior art date
Application number
BRPI0518191-7A
Other languages
English (en)
Inventor
Seo Hong Yoo
Original Assignee
Seo Hong Yoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seo Hong Yoo filed Critical Seo Hong Yoo
Publication of BRPI0518191A publication Critical patent/BRPI0518191A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA REDUZIR A TOXICIDADE DE UM COMPOSTO FARMACêUTICO. A presente descrição se refere a soluções aquosas claras de um ou mais ácidos biliares e/ou um produto de conversão de amido solúvel aquoso ou um polissacarídeo não amido. As soluções da descrição podem ser administradas a um sujeito em conjunto com um composto farmacêutico dotado de um ou mais efeitos tóxicos. Em algumas modalidades, as soluções da descrição são administradas a um mamífero em conjunto com um composto farmacêutico associado com neurotoxicidade periférica (por exemplo, cispíatina e/ou suramina) para reduzir ou eliminar o(s) efeito(s) neuropático(s).
BRPI0518191-7A 2004-10-15 2005-10-14 métodos e composições para reduzir a toxicidade de um composto farmacêutico BRPI0518191A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61919904P 2004-10-15 2004-10-15
PCT/US2005/037211 WO2006044771A2 (en) 2004-10-15 2005-10-14 Methods and compositions for reducing toxicity of a pharmaceutical compound

Publications (1)

Publication Number Publication Date
BRPI0518191A true BRPI0518191A (pt) 2008-11-04

Family

ID=36203610

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518191-7A BRPI0518191A (pt) 2004-10-15 2005-10-14 métodos e composições para reduzir a toxicidade de um composto farmacêutico

Country Status (11)

Country Link
US (1) US7932243B2 (pt)
EP (1) EP1809330B1 (pt)
JP (1) JP2008516977A (pt)
KR (1) KR20070084211A (pt)
CN (1) CN101039699B (pt)
AT (1) ATE506955T1 (pt)
AU (1) AU2005295541B2 (pt)
BR (1) BRPI0518191A (pt)
CA (1) CA2584184A1 (pt)
DE (1) DE602005027727D1 (pt)
WO (1) WO2006044771A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
KR20070084211A (ko) 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
CN101410123A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的双氯芬酸和β－环糊精的制剂
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
JP2010503667A (ja) * 2006-09-15 2010-02-04 ホン ユー，ソ 大腸疾患用胆汁製剤
RU2500408C2 (ru) * 2008-06-06 2013-12-10 Н.В. Нютрисиа Способ предотвращения использования кортикостероидов
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
LT2616064T (lt) 2010-10-21 2019-11-25 Rtu Pharmaceuticals Llc Parengtos naudoti ketorolako kompozicijos
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
KR20170008252A (ko) * 2014-05-09 2017-01-23 아우로메딕스 파마 엘엘씨 사이클로포스파미드 액상 농축 제제
AU2015278833B2 (en) 2014-06-27 2018-12-06 Medytox Inc. Methods and compositions of bile acids and salts for reduction of fat
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
US12569502B2 (en) * 2019-11-01 2026-03-10 Peking University Use of bile acids and derivatives thereof in preparation of GPR39 agonist

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2148890A5 (pt) * 1971-08-09 1973-03-23 Peugeot & Renault
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4092428A (en) 1973-11-02 1978-05-30 Yamanouchi Pharmaceutical Co., Ltd. Process of preparing stable prostaglandin E group-containing formulation
US4036954A (en) 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
JPS5522616A (en) 1978-08-04 1980-02-18 Tokyo Tanabe Co Ltd Bile acid inclusion compound and injection containing the same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
FR2521430A1 (fr) 1982-02-12 1983-08-19 Pan Medica Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPS61171421A (ja) 1985-08-23 1986-08-02 Yamanouchi Pharmaceut Co Ltd 安定なプロスタグランジンｅ類製剤の製造方法
JPS62153220A (ja) 1985-12-27 1987-07-08 Tokyo Tanabe Co Ltd 胆汁酸内用水剤
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0747539B2 (ja) 1986-10-22 1995-05-24 東京田辺製薬株式会社 胆汁酸固形製剤
JPS63243031A (ja) 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
DE3886880T2 (de) 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5446026A (en) 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
DK0527153T3 (da) 1990-04-04 1996-11-25 Berwind Pharma Service Vandige filmovertræk af maltodextrin og cellulosepolymerer
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
CH680704A5 (pt) 1991-05-15 1992-10-30 Medichemie Ag
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5342934A (en) 1992-06-19 1994-08-30 The Trustees Of Columbia University In The City Of New York Enantioselective receptor for amino acid derivatives, and other compounds
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
IT1255968B (it) 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5863550A (en) 1993-03-31 1999-01-26 Tokyo Tanabe Company Limited Cholestasis ameliorant
LU88375A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Produit énergétique stimulant la puissance virile
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
DE59407041D1 (de) 1993-08-30 1998-11-12 Medichemie Ag Ursodeoxycholsäure enthaltendes Arzneimittel in flüssiger Darreichungsform
GB9405833D0 (en) 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
DE4432708A1 (de) 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5686588A (en) 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
JP2000507938A (ja) 1996-03-22 2000-06-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US6596712B2 (en) * 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE29717252U1 (de) 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
JP3541007B2 (ja) 1998-05-28 2004-07-07 メディプレックス コーポレイション、コリア 両親媒性ポリサッカリド誘導体
US6407117B1 (en) 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
RU2224523C2 (ru) * 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
EP1471870B1 (en) 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
EP1255566A2 (en) * 2000-02-04 2002-11-13 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
AU2001273485A1 (en) 2000-07-18 2002-01-30 The Nutrasweet Company Drying of neotame with co-agents
US20030044413A1 (en) 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
KR100368936B1 (ko) * 2000-10-04 2003-01-24 주식회사 대웅 우루소데옥시콜린산을 함유한 환경호르몬 독성의 예방 및치료제
AU2003261424A1 (en) 2002-08-06 2004-02-23 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
KR20050103185A (ko) 2002-11-07 2005-10-27 리전츠 오브 더 유니버스티 오브 미네소타 출혈과 관련된 신경계 손상의 치료 방법
CN1770975A (zh) 2003-04-02 2006-05-10 明尼苏达大学评议会 提高细胞生存能力的方法
DE602005019582D1 (de) * 2004-08-30 2010-04-08 Seo Hong Yoo Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
KR20070084211A (ko) 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
EP1819318A1 (en) * 2004-11-24 2007-08-22 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation

Also Published As

Publication number Publication date
DE602005027727D1 (de) 2011-06-09
CA2584184A1 (en) 2006-04-27
KR20070084211A (ko) 2007-08-24
AU2005295541A1 (en) 2006-04-27
WO2006044771A3 (en) 2007-03-29
EP1809330B1 (en) 2011-04-27
US7932243B2 (en) 2011-04-26
EP1809330A2 (en) 2007-07-25
AU2005295541B2 (en) 2011-02-17
US20060188530A1 (en) 2006-08-24
CN101039699A (zh) 2007-09-19
WO2006044771A2 (en) 2006-04-27
JP2008516977A (ja) 2008-05-22
CN101039699B (zh) 2011-07-27
ATE506955T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
BRPI0518191A (pt) métodos e composições para reduzir a toxicidade de um composto farmacêutico
WO2006050165A3 (en) Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
MX2010009336A (es) Composiciones farmaceuticas acuosas que contienen complejos de borato-poliol.
MX336032B (es) Composicion nutricional para promover el balance y salud de la microbiota intestinal.
UA94052C2 (uk) Похідні піридазину
WO2012084624A9 (en) Compositions of fat-soluble active ingredients containing plant protein-soy polysaccharide complexes
ATE479453T1 (de) Polymermischungen von anionischen und kationischen polysacchariden und verwendung davon
EP4449881A3 (en) A colouring composition comprising starch derivatives as a hydrocolloid
WO2010035122A3 (fr) Complexe constitue d'un polysaccharide et d'une hpb
WO2005072745A3 (en) Aqueous solutions comprising prednisolone and a cyclodextrin derivative
WO2002100437A3 (en) Ophthalmic compositions comprising hyaluronic acid
WO2010122385A8 (fr) Formulation a action rapide d'insuline
IN2012DN05020A (pt)
WO2009077693A3 (fr) Compositions comprenant au moins un derive de l'acide naphtoique, du peroxyde de benzoyle et au moins un agent filmogene
MX340829B (es) Polimeros solubles ramificados de glucosa para dialisis peritoneal.
ATE544444T1 (de) Zusammensetzungen für die nasale abgabe
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BRPI0707488B8 (pt) método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
BRPI0717458A8 (pt) Utilização cosmética por via oral e/ou parenteral da glicosamina e da associação da glicosamina e pelo menos um composto polifenol, processo cosmético, composição para administração oral, e, complemento alimentar ou alimento funcional
UA98180C2 (ru) Кислотный полисахарид, способы его получения, местная композиция и ее применение
WO2010041832A3 (ko) 패 유래 화합물 함유 항산화 활성 조성물
MX2008012943A (es) Derivados azaheterociclico de androstanos y androstenos como medicamentos para trastornos cardiovasculares.
ATE485261T1 (de) Salicylsäurederivate
WO2008051793A3 (en) Method of preventing or treating metabolic syndrome
SG162734A1 (en) Compositions comprising nebivolol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.